Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers

被引：5
|
作者：
Zelnak, A. B.
Harichand-Herdt, S.
Styblo, T. M.
Rizzo, M.
Gabram, S. G. A.
Bumpers, H. L.
Hermann, R. C.
Srinivasiah, J.
Schnell, F. M.
O'Regan, R.
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Emory Univ, Dept Surg, Atlanta, GA 30322 USA
[4] Emory Winship Canc Inst, Atlanta, GA USA
[5] Morehouse Univ, Atlanta, GA USA
[6] Northwest Georgia Oncol Ctr, Marietta, GA USA
[7] Georgia Ctr Oncol Res & Educ, Atlanta, GA USA
[8] Grady Mem Hosp, Georgia Canc Ctr Excellence, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.1118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1118
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Final Results from Phase II Trial of Neoadjuvant Docetaxel and Capecitabine Given Sequentially or Concurrently for HER2-Negative Breast Cancers
    Zelnak, Amelia B.
    Styblo, Toncred M.
    Rizzo, Monica
    Gabram, Sheryl G.
    Wood, William C.
    Harichand-Herdt, Seema
    Kim, Sungjin
    Liu, Yuan
    O'Regan, Ruth M.
    CLINICAL BREAST CANCER, 2013, 13 (03) : 173 - 179
  • [2] A randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for Her2 negative breast cancers.
    Harichand-Herdt, S.
    Zelnak, A.
    Styblo, T.
    Rizzo, M.
    Gabram, S.
    Bumpers, H.
    D'Orsi, C.
    Carlson, K.
    Senior-Crosby, D.
    Sellers, N.
    Pierce, T.
    Hicklin, D.
    Srinivasiah, J.
    Schnell, F.
    Hermann, R.
    O'Regan, R.
    CANCER RESEARCH, 2009, 69 (02) : 337S - 337S
  • [3] Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6)
    Rinnerthaler, G.
    Gampenrieder, S. P.
    Voskova, D.
    Petzer, A.
    Hubalek, M.
    Petru, E.
    Hartmann, B.
    Andel, J.
    Balic, M.
    Melchardt, T.
    Ulmer, H.
    Mlineritsch, B.
    Greil, R.
    CANCER RESEARCH, 2017, 77
  • [4] Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial
    Houpu Yang
    Ling Xu
    Shan Guan
    Xiaopeng Hao
    Zhicheng Ge
    Fuzhong Tong
    Yingming Cao
    Peng Liu
    Bo Zhou
    Lin Cheng
    Miao Liu
    Hongjun Liu
    Fei Xie
    Siyuan Wang
    Yuan Peng
    Chaobin Wang
    Shu Wang
    BMC Cancer, 22
  • [5] Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial
    Yang, Houpu
    Xu, Ling
    Guan, Shan
    Hao, Xiaopeng
    Ge, Zhicheng
    Tong, Fuzhong
    Cao, Yingming
    Liu, Peng
    Zhou, Bo
    Cheng, Lin
    Liu, Miao
    Liu, Hongjun
    Xie, Fei
    Wang, Siyuan
    Peng, Yuan
    Wang, Chaobin
    Wang, Shu
    BMC CANCER, 2022, 22 (01)
  • [6] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
    Barrios, Carlos H.
    Liu, Mei-Ching
    Lee, Soo Chin
    Vanlemmens, Laurence
    Ferrero, Jean-Marc
    Tabei, Toshio
    Pivot, Xavier
    Iwata, Hiroji
    Aogi, Kenjiro
    Lugo-Quintana, Roberto
    Harbeck, Nadia
    Brickman, Marla J.
    Zhang, Ke
    Kern, Kenneth A.
    Martin, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) : 121 - 131
  • [7] Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
    Carlos H. Barrios
    Mei-Ching Liu
    Soo Chin Lee
    Laurence Vanlemmens
    Jean-Marc Ferrero
    Toshio Tabei
    Xavier Pivot
    Hiroji Iwata
    Kenjiro Aogi
    Roberto Lugo-Quintana
    Nadia Harbeck
    Marla J. Brickman
    Ke Zhang
    Kenneth A. Kern
    Miguel Martin
    Breast Cancer Research and Treatment, 2010, 121 : 121 - 131
  • [8] Phase II trial of sequential dose-dense epirubicin/cyclophosphamide (E/C) followed by docetaxel/capecitabine (D/X) as adjuvant or neoadjuvant chemotherapy for patients with HER2-negative breast cancer (BC)
    De la Cruz, S.
    Aramendia, J. M.
    Espinos, J.
    Fernandez-Hidalgo, O.
    Santisteban, M.
    Arbea, L.
    Aristu, J.
    Garran, C.
    Martinez-Monge, R.
    Martinez-Regueira, F.
    Nieto, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
    Rinnerthaler, Gabriel
    Gampenrieder, Simon Peter
    Petzer, Andreas
    Hubalek, Michael
    Petru, Edgar
    Sandholzer, Margit
    Andel, Johannes
    Balic, Marija
    Melchardt, Thomas
    Hauser-Kronberger, Cornelia
    Schmitt, Clemens A.
    Ulmer, Hanno
    Greil, Richard
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [10] A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer
    File, Danielle M.
    Abdou, Yara
    Force, Jeremy
    Moore, Dominic T.
    Anders, Carey K.
    Reeder-Hayes, Katherine
    Carey, Lisa A.
    Muss, Hyman B.
    Perou, Charles M.
    Marcom, P. Kelly
    Dees, E. Claire
    CLINICAL BREAST CANCER, 2024, 24 (08) : 683 - 690
12345